🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hello, World! 🌍🧬 I'm incredibly excited to share this news and thank Jane Chuprin for leading this effort. Let's make radically free biotech education, beyond the most privileged hubs. nucleatehq.medium.com/the-future-of-…

Non-replicating enveloped viral vector, virus like particle, non-viral vesicle, the lines are blurry. Is function/safety all that matters? quantamagazine.org/cells-talk-in-…

We’re thrilled to be selected by AbbVie for their 2022 AIM award! Great work team! Josh Leonard Jay Rosanelli Devin Stranford Hailey Edelstein

Getting ready for Halloween! Devin Stranford

The potential of immune cell therapies will depend on continued investment in and improved access to the enabling elements of their complex technology stack science.org/doi/10.1126/sc…

investors often prefer technical risk and not market risk, but underwriting the creation of new markets has resulted in many of the best investments of all time PCs in every home, cloud-based data storage, ride sharing "the market is too small" is often a failure of imagination

when I was a postdoc w/ George Whitesides at Harvard, George harbored the belief that a hidden driver/requirement of great science was COST.

Every cell in the living world constantly sheds virus-size particles, and these “EVs” are useful for biotechnology. Here we address a key unmet need in EV bioengineering research: counting surface features (accurately) biorxiv.org/content/10.110…

Prediction: Gene editing will be huge. This is just Internet stocks in 2000.